About this Research Topic
However, sustained overproduction of IFN-I can be deleterious for the host. The negative impact of IFN-I is well illustrated by a class of disorders collectively termed type 1 interferonopathies composed of rare monogenic diseases and complex auto-inflammatory/auto immune diseases such as systemic lupus erythematosus (SLE).
Thus, since the last decade, there is a strong increasing scientific and clinical interest in elucidating the biology of IFN-I. Although our understanding of cellular and molecular functions of interferons has tremendously advanced recently, much remains to be learned and IFN-I remains an active and fascinating area of inquiry with promising clinical applications. All studies involving IFN-I, IFN signaling or IFN producing cells in normal or pathologic settings are welcome.
In this Research Topic, we welcome the submission of Original Research, Reviews, Mini Reviews, and Opinion articles focusing on the following subtopics:
1. New insights on type 1 interferonopathies
2. The roles of IFN-I in chronic viral infections
3. New therapies targeting IFN-I
4. Role of interferon producing cells in autoimmunity and inflammatory diseases.
Dr. Herbeuval is the co-founder of Ermium Therapeutics. The other Topic Editors declare no competing interests with regards to the Research Topic theme.
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.